The world’s first potential therapy for an increasingly common, chronic lung condition has been identified following a trial ...

Bronchodilators have a limited role in bronchiectasis management compared ... making antibiotics a mainstay of treatment. Augmented mucus clearance is a crucial complementary approach.

"Brensocatib has the potential to transform the treatment landscape for bronchiectasis and we were pleased to receive the FDA acceptance of our NDA with priority review even earlier than ...

In the assessment of 12-month price targets, analysts unveil insights for Insmed, presenting an average target of $99.0, a ...

These invisible pollutants are damaging your lungs, heart, and brain every day. Read on to know the hidden dangers of ...

Q1 2025 Earnings Call Transcript May 8, 2025 Insmed Incorporated misses on earnings expectations. Reported EPS is $-1.42 EPS, ...

AIIMS Delhi scientists developed India’s first TEM-based method to diagnose rare genetic disorder PCD, boosting accuracy and ...

Tactile Systems Technology, Inc.’s TCMD share price has dipped by 33.21%, which has investors questioning if this is right ...

Learn more about whether Exact Sciences Corporation or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.

Altesa BioSciences today announced positive topline results from its Phase 2 placebo-controlled study examining the effects of vapendavir in COPD patients challenged with rhinovirus.  In this study, ...

A mum has spoken of how a charity provided a "lifeline" for her family while her daughter underwent a bone marrow transplant.